CDX2 and cancer: Furthermore, explorative analyses within the chemo‐naïve stage I–III subgroup suggest that CDX2 carries prognostic information for cancers with BRAF mutations, within both the MSI and MSS subtypes separately, highlighting CDX2 as a potential biomarker with additional prognostic information to MSI and BRAF status.